Literature DB >> 3385738

Screening for fetal and genetic abnormality: social and ethical issues.

G R Dunstan1.   

Abstract

In answer to questions raised by practitioners, an ethics of genetic screening is located in a tension between liberty and responsibility in three respects: (1) to nature and biological processes; (2) to the disposal of human life; and (3) to the relation of persons to society. Under (1), the obligation to pursue research, fundamental as well as applied, is affirmed, offering the benefit of economy with fetal life, but requiring discrimination between the beneficial, the trivial, and the bizarre. Under (2) the abortion question, when relevant to diagnosed abnormality, is discussed, not in the language of conflicting rights, but of the relation of duties to interests. Under (3) the familial and social dimensions of screening raise questions of the disclosure of information and the keeping or extending of confidences. Last comes the value placed on truth in two related areas of developing practice. In infertility treatment, the donors of gametes are required to remain anonymous. Gene tracing through families requires for its effectiveness some correspondence between assumed identity and genetic identity. This conflict of social policies should be resolved.

Entities:  

Keywords:  Analytical Approach; Genetics and Reproduction

Mesh:

Year:  1988        PMID: 3385738      PMCID: PMC1050453          DOI: 10.1136/jmg.25.5.290

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  1 in total

1.  Preimplantation diagnosis of deficiency of hypoxanthine phosphoribosyl transferase in a mouse model for Lesch-Nyhan syndrome.

Authors:  M Monk; A Handyside; K Hardy; D Whittingham
Journal:  Lancet       Date:  1987-08-22       Impact factor: 79.321

  1 in total
  1 in total

1.  Systematic scoping review of the concept of 'genetic identity' and its relevance for germline modification.

Authors:  Floor M Goekoop; Carla G van El; Guy A M Widdershoven; Nadza Dzinalija; Martina C Cornel; Natalie Evans
Journal:  PLoS One       Date:  2020-01-24       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.